Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.7 EUR | -3.60% |
|
-1.01% | -4.80% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.24 times its estimated earnings per share for the ongoing year.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.80% | 39.97B | - | ||
+52.93% | 803B | C+ | ||
+40.75% | 631B | B | ||
-7.08% | 351B | C+ | ||
+17.40% | 324B | B- | ||
+10.58% | 303B | C+ | ||
+16.72% | 243B | B+ | ||
+1.88% | 228B | A+ | ||
+10.27% | 217B | B- | ||
+6.24% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- TKD Stock
- Ratings Takeda Pharmaceutical Company Limited